Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at ruxolitinib as treatment for polycythaemia vera (The RELIEF study)
This trial compared ruxolitinib with hydroxycarbamide (hydroxyurea) to see which was better at treating symptoms of polycythaemia vera (PV).
More about this trial
Polycythaemia vera is a condition in which the bone marrow makes too many red blood cells. It is one of a group of conditions called myeloproliferative disorders. It is closely related to leukaemia.
Doctors usually treat PV with hydroxycarbamide. But some people still have symptoms such as tiredness, itching, aching muscles and sweating. So researchers are looking for other treatments.
Ruxolitinib is a targeted cancer drug. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow. Ruxolitinib may help to relieve the symptoms of polycythaemia vera.
The aims of this trial were to find:
- if ruxolitinib reduced the symptoms of polycythaemia vera more than hydroxycarbamide
- how safe it was
Summary of results
The trial team found that ruxolitinib controlled the symptoms of polycythaemia vera only slightly better than hydroxycarbamide.
This was a phase 3 trial. 110 people took part. They were put into treatment groups (
- 54 people had ruxolitinib
- 56 people had hydroxycarbamide
At 16 weeks of treatment researchers were looking for a decrease of half or more (50% or more) in the following group of symptoms:
- muscle aches
- night sweats
- sweats while awake
In the ruxolitinib group they had the results for 53 people. Of these 23 (43.4%) people had a 50% or more decrease in their symptoms.
In the hydroxycarbamide group the team had the results for 54 people. Of these 16 (29.6%) had a 50% or more decrease.
However the team considered this difference not to be
Researchers also compared the decrease of individual symptoms between the 2 groups. The greatest difference between the individual symptoms of the groups was itching. The team considered this difference to be statistically significant.
After 16 weeks people were told which group they were in. People taking ruxolitinib were able to continue doing so. People taking hydroxycarbamide were able to crossover and have ruxolitinib instead of hydroxycarbamide.
In the ruxolitinib group 34 people decided to continue with the treatment.
In the hydroxycarbamide group 36 people decided to crossover and have ruxolitinib.
Ruxolitinib benefited both these groups by reducing their symptoms.
The most common side effects of ruxolitinib included:
The most common side effects of hydroxycarbamide included:
Blood clots occurred in 1 person who had ruxolitinib and 6 people who had hydroxycarbamide.
The team concluded that, compared with hydroxycarbamide, ruxolitinib did reduce the symptoms of polycythaemia vera but the difference wasn’t statistically significant. They also concluded that ruxolitinib is better than hydroxycarbamide at controlling the individual symptom of itching.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Yasmin Hasan
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040